WO2012030977A1 - Biocapteur endoscopique sans fil pour la détection en temps réel d'un saignement gastro-intestinal - Google Patents

Biocapteur endoscopique sans fil pour la détection en temps réel d'un saignement gastro-intestinal Download PDF

Info

Publication number
WO2012030977A1
WO2012030977A1 PCT/US2011/049992 US2011049992W WO2012030977A1 WO 2012030977 A1 WO2012030977 A1 WO 2012030977A1 US 2011049992 W US2011049992 W US 2011049992W WO 2012030977 A1 WO2012030977 A1 WO 2012030977A1
Authority
WO
WIPO (PCT)
Prior art keywords
patient
chemical
sensor housing
tract
sensor
Prior art date
Application number
PCT/US2011/049992
Other languages
English (en)
Inventor
Nicholas Barker
Christopher C. Thompson
Robert Westervelt
Alex Nemiroski
Keith L. Obstein
Original Assignee
Endolumina Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2010/058061 external-priority patent/WO2011066431A2/fr
Application filed by Endolumina Inc. filed Critical Endolumina Inc.
Publication of WO2012030977A1 publication Critical patent/WO2012030977A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/42—Detecting, measuring or recording for evaluating the gastrointestinal, the endocrine or the exocrine systems
    • A61B5/4216—Diagnosing or evaluating gastrointestinal ulcers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/07—Endoradiosondes
    • A61B5/073—Intestinal transmitters

Definitions

  • the invention generally relates to the field of wireless biosensor devices. More particularly, the invention relates to a swallowable wireless biosensor device that can provide real-time detection of gastrointestinal hemorrhage within a patient.
  • a system for detecting bleeding or blood in the Gl tract of a patient may include a sensor housing containing an optical system including a light source, a light sensor, and a transmitter, each linked to a controller within the sensor housing , or a non-optical sensor system may be used.
  • a chemical source in or on the sensor housing may be provided, with the chemical changing color or other property upon contact with blood in the Gl tract.
  • the sensor housing is sized and shaped so that it can be swallowed by the patient.
  • a receiver outside of the patient receives signals from the transmitter in the swallowed sensor housing. If blood is present, the system can detect the resulting change in color or other detected condition, and transmit corresponding information to the receiver.
  • a system for detecting bleeding in the Gl tract of a patient may include a sensor housing sized and shaped to be swallowed by a patient, with the sensor housing containing a sensor and a transmitter, each linked to an electronic controller and an electrical power source within the sensor housing.
  • the sensor is this design is capable of chemically or optically detecting an intravenously introduced chemical present in the Gl tract of the patient.
  • a receiver is provided in the system to receive signals from the transmitter indicative of the presence and/or absence of the chemical.
  • the chemical for example fluoroscein, is introduced intravenously into the patient. If the patient has bleeding in the Gl tract, the chemical will be present in the Gl tract and will be detected by the system.
  • a sensor system within a swallowable sensor housing is activated or turned on.
  • a wireless communication link between the sensor system and a receiving system is established and confirmed.
  • the patient then swallows the sensor housing.
  • a Gl chemical marker is provided into the Gl tract.
  • the Gl chemical marker may be provided in or on the sensor housing.
  • the Gl chemical marker changes color upon contact with blood in the Gl tract.
  • a light source within or on the sensor housing is turned on or flashed periodically. If blood is present in the Gl tract, the Gl chemical marker changes color, with the color change then detected via a color detector on or in the sensor housing. Information about the detected color change is transmitted from the sensor housing to the receiving system.
  • the color change may be analyzed by an electronic processor within the sensor housing, or in the receiving system, to determine whether the color indicates presence of blood.
  • the sensor in the sensing housing is adapted to sense an IV chemical intravenously introduced into the patient.
  • the sensor may be an optical sensor or a chemical sensor.
  • Fig. 1 is an illustration of one implementation of a medical sensor system including a plurality of Wireless Biosensor Devices (WBDs) implanted within a patient.
  • WBDs Wireless Biosensor Devices
  • FIG. 2 is a schematic illustration showing various components of a WBD, including a power source and fastening clip.
  • Fig. 3 illustrates one specific implementation of a WBD having a photodiode, battery, and pH sensor.
  • Fig. 4 is an illustration of an example of a ZigBee-based network tree for implementing one embodiment of the system and device.
  • Fig. 5 is a schematic diagram of a WBD.
  • Fig. 6 is a flow chart of a method of the invention. DETAILED DESCRIPTION
  • the system includes a Wireless Biosensor Device (WBD).
  • the WBD can be placed inside a patient's body or attached to another location in, on or near the patient as needed.
  • the WBD can be designed in a size and shape so that it can be swallowed by a patient.
  • the WBD may also be designed to attach inside a patient.
  • the WBD can be endoscopically attached to a patient's Gl tissue with, for example, a biodegradable suture or a clip or fastener, or may be included with its own attachment mechanism.
  • the WBD can include a radio communication subsystem for communicating with one or more devices located external to the patient.
  • the radio communications subsystem may be compliant to IEEE 802.1 5.4, thus providing integration with external networks and other biosensor devices. For example, many hospital systems are now computerized and wirelessly networked; allowing data from the WBD can be directly integrated with such a system.
  • Fig. 1 is an illustration of one implementation of a medical sensor system including a plurality of WBDs inside a patient.
  • WBDs 10 can be swallowed by a patient and can be configured to detect one or more biological conditions of patient 12. WBDs 10 can then communicate biological data describing the condition to a monitor 14 through a wireless communication network. Monitor 14 can be mounted near the skin of patient 12 to improve communication between WBDs 10 and monitor 14. Alternatively, monitor 14 can be worn as a pendant.
  • Monitor 14 is also configured to communicate with external systems 16 such as cell phone or other computers, servers, or medical personnel to relay data describing a condition of patient 12 or to provide information and/or warnings directly to patient 1 2 through a communication mechanism such as a visual interface, speaker, or vibration device.
  • external systems 16 such as cell phone or other computers, servers, or medical personnel to relay data describing a condition of patient 12 or to provide information and/or warnings directly to patient 1 2 through a communication mechanism such as a visual interface, speaker, or vibration device.
  • the system can include a variety of sensors including, for example, sensors for the measurement of pH, pressure, and/or specific chemicals, proteins or peptides. Such chemicals, proteins or peptides may be endogenous to the patient or be administered to the patient, or be produced by another entity, for example, by a commencile micro-organism in the patient.
  • An optional optical system for providing both illumination and spectrally filtered detection of scattered light can be included within WBD 10 for direct color detection using RGB filters or using a filtered photosensor to detect fluorescence from a medical biomarker used to label blood.
  • the blood can be fresh, i.e. resultant from a recent bleed or a currently active bleed or it can be old, i.e. resultant from a less recent bleed or a currently inactive bleed.
  • a non-optical sensing of a change in another property may be performed.
  • the optical sensors can be implemented by a photonic integrated circuit (PIC).
  • PIC photonic integrated circuit
  • the WBD 10 can then transmit the detected color and/or fluorescence information to a monitor 14.
  • the monitor 14 can perform analysis on the color data, or forward the information to another party or device for analysis.
  • the systems and devices can be configured to perform optical detection of fluorescent dyes which can serve as proxies for fresh blood.
  • the dyes when excited by light of an appropriate wavelength, relax and emit photons at a lower energy.
  • the optical system can include a colored LED providing the initial biomarker excitation and adjacent photodiodes filtered to detect any fluorescence.
  • Multilayer optical filters can be engineered to separate the spectrum of the fluorescence from the LED excitation.
  • multiple photodetectors sensitive to different wavelengths detect the peak of the emission spectrum through second derivative analysis. Using these techniques, appropriately tagged substances, such as blood or food, can be detected and differentiated from untagged substances.
  • the systems and devices detect fresh blood using an optical system to detect an electrochemical reaction via a color change.
  • a metal ion for example, stannous chloride, which is currently administered for technetium-labeling of red- blood cells in bleeding scans.
  • This metal ion can serve as a proxy for fresh blood. It also can serve as a reducing agent for a substance that can be present in the WBD. This substance can be a metal, such as, for example, gold or molybdenum.
  • the systems and devices can detect blood (either old or new) via an optical system that detects a chemical reaction via a color change.
  • an optical system that detects a chemical reaction via a color change.
  • One way of achieving this is by providing guaiac resin with the device. This resin turns a bright blue color upon contacting blood. Therefore, optical detection of this color change can reflect hemorrhage, old or new.
  • the systems and devices can detect, in real time, molecules that are indicative of the presence of H. pylori. For instance, the system and device can detect excess urea in the patient's stomach. Similarly, as chemical or biomedical markers for other diseases such as cancer are discovered and or publicized, the system can be adapted to detect these markers as well.
  • Measurement of pH and pressure by the systems and devices can facilitate determination of the device's location within the gastrointestinal tract.
  • the transition of the device from the stomach to the small intestine will reflect a change from an acidic environment to a more neutral or slightly alkaline environment (provided the patient is not taking any medications for gastric acid suppression).
  • the transition of the device from the stomach to the small intestine will reflect a change in the pattern as well as the intensity of peristaltic waves. Understanding the location of the device within the gastrointestinal tract can help determine the source of hemorrhage.
  • the device may also be located in vivo by ultrasound, which is present in most emergency rooms. Radiofrequency tagging (RFID) within the WBD may also optionally be used.
  • RFID Radiofrequency tagging
  • An external hand-held device may alternatively locate the internal position of the swallowed WBD by emitting a sound or flashing an LED light when it passes over the WBD.
  • a magnet may also be used for locating the device.
  • an external hand-held device with a built-in Reed switch could demonstrate the internal position of the WBD. In the presence of a magnet, the Reed switch closes, thereby completing the circuit and flashing a LED light or emitting a sound.
  • the systems and devices can operate externally of the patient's body.
  • the device when used in the detection of H. pylori, can be used to detect substances in feces that are expelled from the patient.
  • the device can also be used to detect substances in sputum expelled from the patient for diagnosing respiratory tract infections or to detect substances in urine expelled from the patient for diagnosing urinary tract infections.
  • the systems and devices can also include an ultra-low power microprocessor chip, including, for example, sensor inputs and flash memory for controlling the WBD 10.
  • the microprocessor can be programmed to allow the WBD 10 to be configured for a range of applications.
  • the microprocessor of WBD 10 can be in communication with the monitor 14 located external to the patient.
  • a WBD 10 uses a wireless communication protocol to transmit data to a monitor 14. Having received the data, the monitor 14 can transmit the data to computers or servers that are in communication with the monitor 14, or display or otherwise communicate the information to a user of the system (e.g., a patient, doctor or any medical service provider that wishes to review the biological data, amongst others).
  • a user of the system e.g., a patient, doctor or any medical service provider that wishes to review the biological data, amongst others.
  • the monitor 14 allows a user of the system to extract data from one or more WBDs 10, wirelessly control and program WBDs 1 0, form a network of internal sensors, and connect to existing communication networks (e.g., mobile phone networks, the Internet, etc.) for remote monitoring of patients or for emergency contact with the medical facility.
  • existing communication networks e.g., mobile phone networks, the Internet, etc.
  • Each monitor 14 may act as a node in a Body Sensor Network (BSN).
  • BSN Body Sensor Network
  • the monitors can include an antenna attached to a surface of the patient to provide an improved Radio Frequency (RF) connection with the internal WBDs.
  • RF Radio Frequency
  • WBDs 10 and monitor 14 can use standard communication protocols to establish wireless network connections between monitors 14 at different locations on the body.
  • one monitor can act as a router or network controller to relay data generated by each WBD to a medical facility via the Internet, cellular phone network, or other communication network, using a Bluetooth wireless networking protocol, for example.
  • a BSN with strategically placed WBDs 10 can be used, for example, in the diagnosis, monitoring, and treatment of a diverse range of gastroenterological problems.
  • a WBD 10 with the appropriate optical filter can be configured to recognize a fluorescent substance to identify tagged substances, such as fresh blood or food. After detecting one or more of these potential medical indicators, the WBDs 10 can transmit the collected data to the monitors 14.
  • the monitors 14, after receiving the data, can alert the patient to the condition, or forward the data to a medical center, doctor or other entity for analysis. In this manner, various medical conditions, such as, for example, ulcer bleeding can thus be immediately addressed.
  • the molecule used to generate a signal can be fluorescein.
  • Quinine may also be used because it is readily detected using fluorescence and has a half life (1 9 hours), making it suitable for detection.
  • Quinine is also excreted renally, reducing the possibility of false positive detection in the digestive system.
  • Quinine can be administered in a number of manners, for example, orally or intravenously.
  • Feridex may also optionally be used to generate a signal.
  • Feridex is often used for MRI contrast imaging.
  • Feredex consists of iron and carbohydrates. It can be administered intravenously, and is taken up by reticuloendothelial system (RES) cells (including cells of the liver, lymph nodes, and spleen, amongst others). In the liver, the iron dissociates from the carbohydrates and enters the normal iron metabolic pathways. The half-life of molecule is 2.4 hours. The carbohydrate component is renally excreted. The elemental iron is retained in the body for 14-28 days.
  • RES reticuloendothelial system
  • feraheme which has characteristics similar to feridex but contains 10-15 times the amount of elemental iron, and gadolinium (gadopentate dimeglumine), a para-magnetic agent frequently used for MRI contrast imaging.
  • gadolinium gadopentate dimeglumine
  • This molecule which can be administered intravenously, is renally excreted. Its excretion kinetics are as follows: 80% of the molecule is excreted by 6 hours; 91 % is excreted by 24 hours. Methylene blue or an isosulfan dye may similarly be used.
  • Metal ions may also be used to generate a signal. These ions, including Tc, Sn, Cu and Sn, amongst others, may be adequately detected electrochemically or potentiometrically in a biosensor system or device. Tc, in the form of DTPA, which is renally cleared, can be used.
  • Fig. 2 is a schematic illustration showing various components of a WBD 10, including a power source 30.
  • the WBD 10 includes a casing 32 to contain and protect several of the components of the WBD 10.
  • the casing 32 can include any material that can withstand the Gl tract environment such as medical grade metals, plastics, or composites.
  • the casing can also be smooth in texture and shaped to facilitate swallowing and minimize the risk of damage to the Gl tract during transit.
  • the casing may be coated with a polymer, for example, Hypromellose ( hydroxypropylmethylcellulose) (HPMC), a semi synthetic, inert, viscoelastic polymer used as an ophthalmic lubricant or tablet coating material.
  • HPMC hydroxypropylmethylcellulose
  • a semi synthetic, inert, viscoelastic polymer used as an ophthalmic lubricant or tablet coating material.
  • HPMC hydroxypropylmethylcellulose
  • the casing 32 contains a power source 30 for powering the electronics of the WBD 10.
  • the power source 30 can be connected to electronic systems 36, 44, and sensors 38a-c, 40 and 42, to provide electrical energy and can include a battery, capacitor, or other energy storing or generation device.
  • the electronic and sensor system 36 contains the primary electronic and sensor systems for the WBD 10, while the electronic and sensor systems 44 contain secondary systems.
  • Electronic systems 36 and 44 can include microprocessors, flash memory or other data storage mechanisms, and radio modulation systems for implementing the functionality of WBD 10.
  • Fig. 3 illustrates an embodiment of WBD 10 having a photodiode, a battery and a pH sensor.
  • Fig. 3 shows some of the internal components of the WBD 10, including a power source or battery 64, an electronics chip 66 connected to a sensor 68 and filtered diodes 70a-c, antenna connectors 74 and an LED 72.
  • An external casing allows for the device to be swallowed.
  • Each WBD 10 can be wirelessly connected to one or more monitors 14 located on the surface of the body of the patient using wireless communication protocols.
  • one or more of the monitors 14 can act as a gateway between the BSN and a mobile phone network or the Internet, i.e. through a Bluetooth connection.
  • Each monitor 14 can be further configured to display information or warnings to the patient, such as by flashing an LED or displaying information on an LCD screen. The warnings can also be relayed to a medical facility, along with real-time data by monitors 14 via a suitable communications network.
  • Each WBD 10 communicates with each monitor 14 using a wireless communications protocol.
  • a first system implementation of the WBD 10 includes an ultra-low power radio frequency (RF) chip connected to the clips of the WBD 10 to generate a radiated signal.
  • Control of the system can be implemented by a low power microprocessor (for example, less than 30 microwatts ( ⁇ )).
  • the radio system, microprocessor, and a flash memory subsystem can all be contained, for example, on a single ultra-low power chip, such as the ChipCon CC2430 or the Ember EM250. Power consumption can be reduced to very low levels by keeping WBD 10 in sleep mode until it is awakened by an external query from the monitor 14, or another system component.
  • the WBD 10 can then transmit short data packets containing the biological data.
  • the WBD 10 can be configured to use Radio Frequency ID (RFID) technology to broadcast biological data to the monitor 14.
  • RFID Radio Frequency ID
  • the monitor 14 illuminates the WBD 10 with an RF signal.
  • the WBD 10 transmits a reflected RF signal to the monitor 14.
  • the reflected RF signal can be modulated by alternately connecting the two halves of the dipole antenna formed by the clips of the WBD 10 using a Field Effect Transistor (FET). Any such modulation of the reflected RF signal can encode data, and, when using an appropriate multiplexing protocol, be read out by the monitor 14.
  • FET Field Effect Transistor
  • Any such modulation of the reflected RF signal can encode data, and, when using an appropriate multiplexing protocol, be read out by the monitor 14.
  • each WBD 10 consumes only relatively low amounts of power as the RF carrier is generated outside the patient by the monitor 14, thus enhancing the battery lifetime of WBD 10.
  • the WBD 10 may include one or more RFID chips for broadcasting information to the monitor 14. Each RFID chip in the WBD 10 has the single task of returning its hard-coded ID number upon receiving a radio query.
  • the WBD 10 can respond to the radio query by broadcasting one of the two ID numbers. In that case, the broadcast of one ID number can signify "OK" while the broadcast of the other ID number can signify "Emergency" (for example, after the WBD 10 has detected bleeding).
  • the dielectric constant of the stomach can be approximately 68 £S to 62 £S for RF frequencies in the range of 400 MHz to 2.4 GHz with free space wavelengths of 75 cm to 12.5 cm.
  • the free space wavelengths correspond to wavelengths in the stomach of 9.1 cm to 1 .6 cm.
  • the signal carrier frequency is set to approximately 2.4 GHz.
  • the power of an isotropically radiated 2.4 GHz signal, detected immediately outside the body (-10 cm away) is attenuated 40 to 60 dB by absorption and by the solid angle covered by the receiving antenna.
  • the ChipCon CC2430 chip has RF output power 0.6 dBm (1 .15 mW) and a receiver sensitivity of -92 dBm. Assuming 60 dB attenuation of the signal during propagation, a reliable wireless link can be established, with a margin of approximately 30 dB.
  • the monitors 14 can be placed at convenient locations outside the body on a surface of the patient 12. To improve the RF link between the monitor 14 and the WBD 10, the monitors 14 can be attached to the skin of the patient using an adhesive such as an adhesive medical patch, or other mechanical coupling mechanisms. Because the monitors 14 are generally mounted outside the body, the power consumption of the monitor 14 is not a primary concern, unlike the power consumption of the WBD 10. As such, the monitors 14 can be assigned relatively high-power consumption responsibilities such as supplying a wireless carrier signal for communication, performing a majority of the data analysis, or implementing remote networking.
  • the monitors 14 can form a wireless network that establishes a data connection between a number of WBDs 10 and monitors 14 at different locations around the body.
  • a monitor 14 can also act as a router, to connect the BSN to external system components via a cell phone network, the Internet, or other communications network to relay alarms and data to a remotely located medical facility. If many WBDs 10 are scattered throughout the Gl tract, multiple WBDs 10 can provide a wireless link between any pair of sensors, regardless of the physical distance. Additionally, the collection of monitors 14 located about the body can enable the system to triangulate the position of each WBD 10 by measuring the power of the RF signal of WBD 10 within their wireless reach, which decays via signal attenuation and spreading loss.
  • Each WBD 10 and monitor 14 may be configured to implement the IEEE 802.15.4 (ZigBee) wireless communication standard for communicating data between each of the WBDs 10 and monitors 14.
  • the standard is oriented towards the implementation of a low cost, ultra-low-powered, long-life wireless sensor network for home automation, remote sensing, energy management, hospital care, and telecommunication.
  • ZigBee technology has been developed and miniaturized to offer a more powerful alternative to RFIDs.
  • Each monitor 14 operates as a router between a WBD 10 star network and other monitors 14, forming a mesh network at the ZigBee Router level.
  • One monitor 14 is designated the ZigBee Coordinator.
  • the Coordinator can communicate with a local computer or mobile phone via a communications network, enabling remote patient monitoring.
  • a monitor 14 simultaneously functions as both a Router and Coordinator.
  • the simplest network of a single monitor 14 and single WBD 10 can still enable communication with external networks (e.g., Internet networks or mobile phone networks).
  • ZigBee networks are comprised of nodes which can have three different roles: ZigBee Coordinator (ZC), ZigBee Router (ZR), and ZigBee End- Device (ZED). Because each ZigBee node can fulfill any of these three roles, the same communication device can be used at each location in the network. The ZED only communicates with its parent ZR, which in turn forms the basis of the ZigBee mesh network, allowing routing of data between any two points in the system.
  • ZC ZigBee Coordinator
  • ZR ZigBee Router
  • ZED ZigBee End- Device
  • One of the ZR routers will be chosen to function as a ZC, being responsible for the synchronization of all nodes, monitoring network topology, dynamically reconfiguring data paths to reflect the current state of the network, and communicating with external networks, such as a cellular phone network, or a computer connected to the Internet to transmit data.
  • each WBD 10 is a ZED
  • each monitor 14 is a ZR
  • one monitor 14' is made a ZC.
  • the ZC monitor 14' can then communicate data received from each WBD 10 to external system components such as a computer 100 or a mobile phone 102.
  • a monitor 14' can transmit data to a medical facility 104 using the Internet 106.
  • the monitor 14' can use a mobile phone 102 and the network to which the mobile phone 102 is connected to transmit data to the medical facility 106.
  • the WBD 10 in order to monitor one or more conditions throughout the Gl tract.
  • the system and device can be configured to sense bleeding, pH, pressure, and bodily fluids (including blood) tagged by fluorescent materials, metal ions, and other exogenous substances or the color changes that take place in the setting of said fluorophore, metal ions, and other exogenous substances.
  • the sensors and electronics can be small enough to be fit inside a WBD suitable for swallowing.
  • An onboard battery or other power source, combined with an programmable ultra-low power microprocessor, flash memory, and RF communication can permit WBD 10 to sense, store, and wirelessly transmit data out of the body to external monitors.
  • the monitors enable the sensors to share data and can also analyze the data to alert the patient of a dangerous condition, and alert a medical facility through a cellular phone network or the Internet.
  • Fig. 5 shows an alternative WBD including a battery 64, voltage regulators 65, an LED 72, a microcontroller 67 with memory 69, A/D converter 71 , digital I/O and Zigbee radio circuitry, optionally within a module 75 or on an ASIC.
  • a crystal oscillator 75, passive decouplers 76 and RF and antenna 77, and an optical sensor 78 are also included.
  • Data on the color detected by the sensor(s) may be processed and analyzed by the microcontroller 67 and stored in the memory 69 shown in Fig. 5. Alternatively, the data may be transmitted to the receiver and processes at the receiver or a computer linked to the receiver.
  • Fig. 6 shows a flow chart of a method of the invention.
  • a chemical marker is released into the Gl tract, optionally from the WBD itself.
  • a flashing filtered LED illuminates the area around the WBD. If no blood is present, no color change is detected and the method ends. If blood is present, the chemical marker changes color. The photodiode then detects the color change, indicative of the presence of blood.
  • the WBD communicates this data to the receiver.
  • the user of the system is instructed to inject an IV chemical into the patient,
  • the IV chemical may be fluoroscein. If the patient is actively bleeding into the Gl tract, the IV chemical will promptly be present in the Gl tract, where it is detected by the WBD and reported to the receiver. The patient is then treated accordingly.
  • the WBD does not detect the IV chemical, this result which is indicative off old blood in the Gl tract, rather than active bleeding (new blood), is similarly transmitted to the receiver.
  • the Gl chemical marker such as guaiac, is referred to as a marker since it produces a color change which is detected, rather than detecting the substance itself.
  • the IV chemical such as fluroscein, on the other hand, is generally detected directly and is referred to as an IV chemical, rather than a marker (although in some cases the IV chemical may also be selected to produce a detectable color change as well).
  • the systems and devices can detect the presence of disease- associated bacteria in the patient.
  • H. pylori is associated with gastric/duodenal ulcers.
  • These systems and devices can provide real time H. pylori detection.
  • the systems and methods are described primarily with reference to human patients, they may be used for treatment of animals.

Abstract

La présente invention concerne un dispositif endoscopique permettant la surveillance d'un paramètre physique et chimique d'un patient, pouvant comporter un boîtier auquel est couplé un capteur. Le capteur peut être configuré pour détecter un paramètre physique ou chimique du patient, tel qu'un saignement gastro-intestinal. Le dispositif comporte un émetteur sans fil pour transmettre un signal à un récepteur externe, le signal codant les paramètres physiques et chimiques du patient détectés par le capteur.
PCT/US2011/049992 2010-09-01 2011-08-31 Biocapteur endoscopique sans fil pour la détection en temps réel d'un saignement gastro-intestinal WO2012030977A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US37912310P 2010-09-01 2010-09-01
US61/379,123 2010-09-01
PCT/US2010/058061 WO2011066431A2 (fr) 2009-11-25 2010-11-24 Système et procédé de surveillance de biocapteur sans fil
USPCT/US2010/058061 2010-11-24

Publications (1)

Publication Number Publication Date
WO2012030977A1 true WO2012030977A1 (fr) 2012-03-08

Family

ID=45773251

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/049992 WO2012030977A1 (fr) 2010-09-01 2011-08-31 Biocapteur endoscopique sans fil pour la détection en temps réel d'un saignement gastro-intestinal

Country Status (1)

Country Link
WO (1) WO2012030977A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022243395A3 (fr) * 2021-05-20 2022-12-29 Enterasense Limited Biocapteurs pour le tractus gastro-intestinal

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050154277A1 (en) * 2002-12-31 2005-07-14 Jing Tang Apparatus and methods of using built-in micro-spectroscopy micro-biosensors and specimen collection system for a wireless capsule in a biological body in vivo
US20070196278A1 (en) * 2004-07-29 2007-08-23 Cold Spring Diagnostics, Inc. Compositions and methods for locating an internal bleeding site
US20080108885A1 (en) * 1998-08-26 2008-05-08 Sensors For Medicine And Science Optical-based sensing devices
US20080262313A1 (en) * 2005-12-07 2008-10-23 Koninklijke Philips Electronics, N.V. Electronic Gastrointestinal Screening
US20090030293A1 (en) * 2005-02-11 2009-01-29 The University Court Of The University Of Glasgow Sensing device, apparatus and system, and method for operating the same

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080108885A1 (en) * 1998-08-26 2008-05-08 Sensors For Medicine And Science Optical-based sensing devices
US20050154277A1 (en) * 2002-12-31 2005-07-14 Jing Tang Apparatus and methods of using built-in micro-spectroscopy micro-biosensors and specimen collection system for a wireless capsule in a biological body in vivo
US20070196278A1 (en) * 2004-07-29 2007-08-23 Cold Spring Diagnostics, Inc. Compositions and methods for locating an internal bleeding site
US20090030293A1 (en) * 2005-02-11 2009-01-29 The University Court Of The University Of Glasgow Sensing device, apparatus and system, and method for operating the same
US20080262313A1 (en) * 2005-12-07 2008-10-23 Koninklijke Philips Electronics, N.V. Electronic Gastrointestinal Screening

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022243395A3 (fr) * 2021-05-20 2022-12-29 Enterasense Limited Biocapteurs pour le tractus gastro-intestinal

Similar Documents

Publication Publication Date Title
US20210204833A1 (en) System and method for wireless biosensor monitoring
AU2017202754B2 (en) Communication system with remote activation
AU2010209278B2 (en) Device,system and method for detection of bleeding
US9041785B2 (en) Multiple capsule camera apparatus and methods for using the same
US8588887B2 (en) Ingestible low power sensor device and system for communicating with same
US20080262376A1 (en) Wireless sensor system for monitoring skin condition using the body as communication conduit
CN101711673B (zh) 食道酸碱度无线监测定位系统、装置及方法
JP2014526918A (ja) 埋め込み型装置を用いた通信システム
JP2009532168A (ja) 生体内分析のための装置、システムおよび方法
EP3678621A1 (fr) Systèmes et procédés d'un dispositif de surveillance de santé
JP4839034B2 (ja) 生体内情報取得装置留置システム
Yuce et al. Wireless telemetry for electronic pill technology
US20100324371A1 (en) Capsule medical device, method for operating the same, and capsule medical device system
WO2012030977A1 (fr) Biocapteur endoscopique sans fil pour la détection en temps réel d'un saignement gastro-intestinal
CN102138794B (zh) 电磁跟踪式全消化道生理信息无创检测系统
US20240081654A1 (en) Bleeding sensor for a patients gastrointestinal tract
KR102255447B1 (ko) 복합 생체신호 측정을 위한 멀티센서 기반 유연 패치 장치 및 이를 이용한 복합 생체신호 측정방법
ES2946268T3 (es) Sistema de detección de alimentación remota con múltiples dispositivos de detección
CN211460132U (zh) 一种探路胶囊及探路胶囊探测系统
CN109714724A (zh) 一种基于Zigbee的病房监控系统

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11822573

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11822573

Country of ref document: EP

Kind code of ref document: A1